Thursday - November 28, 2024
AstraZeneca: Enhertu (fam-Trastuzumab Deruxtecan-Nxki) Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2-Expressing Advanced Solid Tumors
June 06, 2023
WILMINGTON, Delaware, June 6 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 5, 2023:

Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients.

These results will be presented today as . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products